Background: Castleman’s disease is a rare lymphoproliferative disorder that can affect lymph nodes anywhere in the body. Removal of the enlarged lymph nodes may lead to secondary nerve damage, potentially resulting in patients developing complex regional pain syndrome (CRPS) type 2. Spinal cord stimulation (SCS) is a well-established, cost-effective therapy for chronic refractory pain, including CRPS type 2. Case Description: A 32-year-old female who was treated for unicentric hyaline vascular type Castleman’s disease. Following neurolysis, she developed CRPS type 2 of the lumbosacral plexus; her symptoms persisted despite pharmacotherapy and physical therapy. She underwent a trial of burst SCS with significant symptom relief, followed by permanent implantation of a Penta paddle lead at the T8 level. Three months postoperatively, she reported marked clinical improvement and was able to discontinue pregabalin. Conclusion: A 32-year-old female with Castleman’s disease developed CRPS type 2 secondary to neurolysis that was effectively treated with Burst SCS.
Jaffee et al. (2026) studied this question.